1-3 of 3
Alfonso Berrocal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1, first-in-human, dose-escalation, expansion trial of cytokine encoding synthetic mRNA-mixture alone or with cemiplimab in advanced solid tumors

Oliver Bechter, Carmen Loquai, Stephane Champiat, Jean-Francois Baurain, Jean-Jacques Grob, Jochen Utikal, Sylvie Rottey, Alfonso Berrocal, Jessica C. Hassel, Ana Arance, Miguel F. Sanmamed, Marye Boers-Sonderen, Brian Gastman, Christoffer Gebhardt, Brant Delafontaine, Ugur Sahin, Özlem Türeci, Patrick Brueck, Giovanni Abbadessa, Rahul Marpadga, Helen Lee, Yue Yang, Barbara Buday, Gianfranco Di Genova, Hong Wang, Binfeng Xia, Joon Sang Lee, Céleste Lebbe
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-1983
Published: 28 March 2025
View articletitled, A phase 1, first-in-human, dose-escalation, expansion trial of cytokine encoding synthetic mRNA-mixture alone or with cemiplimab in advanced solid tumors
Open the PDF for A phase 1, first-in-human, dose-escalation, expansion trial of cytokine encoding synthetic mRNA-mixture alone or with cemiplimab in advanced solid tumors in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Ángel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez-Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas O. Iannotti, Frank J. Hsu, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 74–81.
https://doi.org/10.1158/1078-0432.CCR-23-0475
Published: 05 January 2024
View articletitled, A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Open the PDF for A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy in another window
Includes: Supplementary data
Journal Articles

Abstract PO-059: COVID-19 in melanoma patients: Spanish register

Maria Gonzalez-Cao, Cristina Carrera, Juan Francisco Rodriguez Moreno, Pedro Rodriguez-Jiménez, Mónica Antoñanzas Basa, Marta Feito Rodríguez, Teresa Puertolas, Eva Muñoz, José Luis Manzano, Ivan Marquez-Rodas, Juan Martín-Liberal, Ainara Soria, Pilar Lopez Criado, Almudena García Castaño, Aram Boada, Pablo Ayala de Miguel, Susana Puig, Guillermo Crespo, Pablo Luna Fra, Cristina Aguayo Zamora, Jesús Gardeazabal, Cayetana Maldonado Seral, Ana Drozdowskyj, Mariano Provencio, Alfonso Berrocal
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): PO-059.
https://doi.org/10.1158/1557-3265.COVID-19-PO-059
Published: 15 September 2020
View articletitled, Abstract PO-059: COVID-19 in melanoma patients: Spanish register